分享到:

治疗光化性角化病的凝胶剂PEP005进入后期临床研究

本报讯 澳大利亚Peplin制药公司近日已开始进行凝胶制剂PEP005(Ingenol Mebutate)的第二项Ⅲ期  (本文共1页) 阅读全文>>

《世界核心医学期刊文摘(皮肤病学分册)》2006年05期
世界核心医学期刊文摘(皮肤病学分册)

评价光化性角化病疗效的可靠方法

Dermatologists treat actinic keratoses to prevent non-melan-oma skin cancer. Evaluation of actinic keratosis therapy depends on reliable measures of the lesions. The commonly used method of directly counting all visible lesions has been shown to be unreliable. We performed a prospective, single blinded study to explore the reliability of body surface area involvement and direct counting of lesions measuring greater ...  (本文共2页) 阅读全文>>

《解剖与临床》1998年04期
解剖与临床

含3%双氯芬酸的2.5%透明质酸凝胶外用治疗光化性角化病的疗效及安全性分析的开放性研究

光化性角化病是由日光诱导的癌前期病变。随着年龄增长或免疫力的下降,其发病率增加,在男性或是皮肤白皙患者,具有遗传素质者,皮损更常见。随年龄老化和紫外线照身...  (本文共1页) 阅读全文>>

《世界核心医学期刊文摘(皮肤病学分册)》2005年02期
世界核心医学期刊文摘(皮肤病学分册)

冷冻治疗光化性角化病的前瞻性研究

Background. Actinic keratoses are the most common actinic lesions on Caucasian skin. Cryosurgery with liquid nitrogen is commonly used to treat actinic keratoses, but there have been few studies examining the true rate of cure in everyday dermatologic practice. Aim. To determine prospectively the true efficacy of cryosurgery as a treatment for actinic keratoses in everyday dermatologic practice. Methods. A prospectiv...  (本文共2页) 阅读全文>>

《国外医学.皮肤病学分册》1983年02期
国外医学.皮肤病学分册

Etretinate治疗光化性角化病——双盲交叉研究

应用新近合成的维生素A酸etretinate(tigason)治疗光化性角化病的患者50例(男36例,女14例),平均年龄71.4岁(50~85岁),平均...  (本文共1页) 阅读全文>>

《世界核心医学期刊文摘(皮肤病学分册)》2005年01期
世界核心医学期刊文摘(皮肤病学分册)

Melan-A无助于发生于光损害皮损的原位黑色素瘤与色素光化性角化病的鉴别

Pigmented actinic keratosis is one of the simulators of early melanoma in situ from severely sun-damaged skin. Close scrutiny of the hematoxylin and eosin stained section does not always allow an unequivocal diagnosis, because it is sometimes difficult to distinguish pigmented keratinocytes from melanocytes. Immunohistochemical stains, such as S-100 and HMB-45, are used routinely to address this problem. Melan-A, als...  (本文共2页) 阅读全文>>